Reactive Thrombocytosis (Secondary Thrombocythemia)

ByJane Liesveld, MD, James P. Wilmot Cancer Institute, University of Rochester Medical Center
Reviewed/Revised Dec 2023
View Patient Education

    Reactive thrombocytosis is an elevated platelet count (> 450,000/mcL [> 450 × 10/L]) that develops secondary to another disorder.

    (See also Overview of Myeloproliferative Neoplasms.)

    Some causes of reactive thrombocytosis include

    There are also congenital familial thrombocytoses such as those due to thrombopoietin and thrombopoietin receptor gene mutations. For thrombocytosis that is not secondary to another disorder, see Essential Thrombocythemia.

    Platelet function is usually normal. Unlike in essential thrombocythemia, reactive thrombocytosis does not increase the risk of thrombotic or hemorrhagic complications unless patients have arterial disease.

    With secondary thrombocytosis, the platelet count is usually < 1,000,000/mcL (< 1000 × 109/L), and the cause may be obvious from the history and physical examination and with confirmatory testing as indicated. Complete blood count and peripheral blood smear findings may help suggest iron deficiency or hemolysis.

    If a cause of secondary thrombocythemia is not obvious, patients should be evaluated for a myeloproliferative neoplasm. Such evaluation may include testing for myeloproliferative neoplasm driver mutations, cytogenetic studies, including Philadelphia chromosome or BCR-ABL assay, and possibly bone marrow examination, especially in patients with anemia, leukopenia, and/or hepatosplenomegaly.

    Treatment of the underlying disorder usually returns the platelet count to normal.

    quizzes_lightbulb_red
    Test your KnowledgeTake a Quiz!
    Download the free Merck Manual App iOS ANDROID
    Download the free Merck Manual App iOS ANDROID
    Download the free Merck Manual App iOS ANDROID